Skip to NavigationSkip to content

entrectinib

Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents

Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent or refractory solid tumours with and without neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) gene fusions in adolescent and child patients.

In the trial, all 11 participants entrectinib  responded to the drug, and two even achieved a complete response. Five of the participants, who had primary high-grade tumours of the central nervous system, also registered an objective response.  

Roche's entrectinib shrinks lung tumours with two-year response duration

Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), showing the drug had long-term effects and reduced tumour size.

ROS1 gene fusions are present in around 1-2% of NSCLC patients, with NSCLC being the most common kind of lung cancer, accounting for 85% of all cases. Additionally, around 30-40% of ROS1-positive NSCLC have brain metastases at the time they receive their diagnosis.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches